^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + GZ17-6.02 (Apoptosis stimulant, Sonic hedgehog inhibitor, Stem cell inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells
Published date:
01/11/2022
Excerpt:
GZ17-6.02 interacted in an additive fashion with palbociclib to kill ER+ breast cancer cells. GZ17-6.02 and palbociclib cooperated to inactivate mTOR and AKT and to activate ULK1 and PERK.
DOI:
10.18632/oncotarget.28177
